Clinical trial
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
NCT00087139 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00087139 |
|---|---|
| Title | Ixabepilone in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Study of a Weekly Schedule of BMS-247550 for Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer |
| Intervention type | Drug |
| Interventions | ixabepilone |
| Enrollment | 124 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2009 |
| Completion | Feb 1, 2011 |
| First posted | Jul 12, 2004 |
| Last update posted | May 9, 2014 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: